Agios Pharmaceuticals Q2 2026 Earnings Report

Agios Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$1.67
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Agios Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $26.42 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Agios Pharmaceuticals Announcement Details

• Quarter: Q2 2026
• Date: 7/30/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, July 30, 2026
• Conference Call Time: 8:00AM ET

Agios Pharmaceuticals (NASDAQ:AGIO) is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations. Tibsovo (ivosidenib) is approved for treating relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation and for certain advanced cholangiocarcinoma patients. Idhifa (enasidenib) addresses AML patients bearing an IDH2 mutation. These targeted therapies represent some of the first metabolism-based oncology treatments on the market.

Beyond its approved products, Agios maintains a diverse pipeline in both oncology and rare genetic diseases. The company is developing mitapivat, a pyruvate kinase activator for chronic hemolytic anemias, in collaboration with Servier for ex-U.S. commercialization. Additional research programs leverage Agios’s expertise in metabolic targets to pursue next-generation candidates for hematologic malignancies and solid tumors. Agios markets its therapies directly in the United States and partners with global pharmaceutical companies for commercialization in Europe and other regions.

Agios went public in 2013 and has maintained its headquarters and core research operations in Cambridge. Leadership is currently headed by President and CEO Jackie Fouse, with Catherine Shacklett serving as Chief Financial Officer. The company continues to expand its scientific capabilities and strategic collaborations as it advances its mission of translating metabolism research into life-changing treatments.